Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
British Journal of Cancer, 05/07/2012
Feun LG et al. – Arginine–depleting therapy with pegylated arginine deiminase (ADI–PEG20) is safe and the drug is only efficacious in melanoma patients whose tumour has negative argininosuccinate synthetase (ASS) expression. Argininosuccinate synthetase tumour positivity is associated with drug resistance and tumour progression.
